SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Hansoh Pharma Combination Extends Progression-Free Survival in Phase 3 Lung Cancer Study

Hansoh Pharma said dalmelitinib plus aumolertinib extended progression-free survival in a Phase 3 lung cancer study.

Related stories